

To Whom It May Concern:

Given that it's been a while since ANH first submitted this petition, I wanted to share some new studies supportive of the statistically significant effects described in the petition. Your team has likely already reviewed these too, but just in case:

Following is a selection (in reverse chronological order):

Evers PD, Madsen N, Farkas D, et al. Proton-Pump Inhibitor Use and Risk of Community-Acquired Pneumonia in Congenital Heart Disease Patients. *Pediatrics* 2021; 147(3): 396. doi: 10.1542/peds.147.3_MeetingAbstract.396

Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. *PLOS ONE* 2019; 14(5): e0216750. <https://doi.org/10.1371/journal.pone.0216750>

Hung TH, Tseng CW, Tsai CC, Lee HF. Effect of proton pump inhibitors on mortality of cirrhotic patients with pneumonia. *PLOS ONE* 2019; 14(4): e0216041. <https://doi.org/10.1371/journal.pone.0216041>

Cohen SM, Lee HJ, Leiman DA, Roy N, Misono S. Associations between Community-Acquired Pneumonia and Proton Pump Inhibitors in the Laryngeal/Voice-Disordered Population. *Otolaryngol Head Neck Surg.* 2019; 160(3):519-525. doi: 10.1177/0194599818811292.

Zirk-Sadowski J, Masoli JA, Delgado J, et al. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults. *J Am Geriatr Soc.* 2018; 66(7): 1332-1338. doi: 10.1111/jgs.15385.